文献速递前列腺增生与排尿功能障碍

FloStent™首次用于BPH所致留置导尿患者的RAPID I研究补充结果

First Use of the FloStent™ for Catheter-dependent Urinary Retention Secondary to Benign Prostatic Hyperplasia: Additional Results From the RAPID I Study.
PubMed 文献 · Urology · 2025-09-16

RAPID I研究另一分支纳入11例BPH相关尿潴留并留置导尿的男性,行门诊FloStent™植入。术后即刻全部拔除导尿管,3个月时8/11(72.7%)仍无需导尿,疼痛评分均为0,5例发生7次不良事件均为非严重且自限。提示FloStent™可作为等待TURP期间的有效过渡方案。

要点

  • 11例BPH尿潴留留置导尿患者门诊植入FloStent™,术后即刻全部拔管。
  • 3个月时72.7%(8/11)维持无导尿状态,疼痛评分均为0。
  • 5例发生7次非严重自限性不良事件,提示耐受性良好。

核心结论

  • FloStent™使多数BPH相关尿潴留患者实现无导尿排尿,耐受性良好,可能成为等待TURP期间的有效过渡方案。

研究设计与样本

  • RAPID I为首次人体临床试验,本报告为其独立分支,纳入11例BPH相关尿潴留并留置导尿、计划行TURP的男性,均门诊植入FloStent™,随访2、6、12周后取出装置并行TURP。

主要发现

  • 全部11例术后即刻实现无导尿状态。
  • 3个月时8/11(72.7%)维持无导尿,其平均IPSS 6.4±6.6、QoL 0.75±1.75、Qmax 9.5±4.8mL/s、PVR 105.4±265.1mL。
  • 基线平均年龄69.0岁、前列腺体积65.3mL、PSA 8.3ng/mL、血肌酐1.0mg/dL、前列腺尿道长度3.4cm。
  • 所有时间点疼痛评分均为0。
  • 5例受试者共发生7次不良事件,均为非严重且自限。

临床怎么用

  • 对于BPH相关尿潴留留置导尿、等待TURP的患者,FloStent™可作为过渡性治疗选择,但需注意部分患者3个月内可能恢复导尿。

局限性

  • 样本量小(11例),为首次人体研究单分支,缺乏对照,随访仅3个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the performance of the FloStent™ in men with catheter-dependent urinary retention due benign prostatic hyperplasia (BPH) awaiting transurethral resection of the prostate (TURP). The FloStent™ is a novel device for treatment of BPH, that can be implanted and retrieved with any flexible cystoscope. METHODS: The RAPID I study was a first-in-human clinical trial designed to evaluate the clinical performance of the FloStent™. One arm of the study treated men with lower urinary tract symptoms. In a separate and distinct arm of the study, reported here, 11 men with BPH-related urinary retention and indwelling catheters were enrolled and scheduled for FloStent™ implantation. All underwent outpatient device placement. Follow-up visits occurred at 2, 6, and 12weeks, after which the device was removed, and subjects underwent TURP as previously indicated. RESULTS: All 11 participants achieved catheter-free status immediately postprocedure. Baseline characteristics included mean age 69.0years, prostate size 65.3 mL, prostate-specific antigen 8.3ng/mL, serum creatinine 1.0mg/dL, and prostatic urethral length 3.4 cm. At 3months, 8 of 11 (72.7%) remained catheter-free. Among those, mean International Prostate Symptom Score was 6.4 ± 6.6, Quality of Life score 0.75 ± 1.75, Qmax 9.5 ± 4.8mL/s, and postvoid residual 105.4 ± 265.1 mL. Pain scores were uniformly 0 across all timepoints. Seven adverse events occurred in five subjects, all nonserious and self-limited. CONCLUSION: FloStent™ enabled catheter-free voiding in the majority of subjects, with excellent tolerability. This approach may offer an effective interim solution for patients awaiting TURP.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chughtai B, Polo J, Perscky I, et al. First Use of the FloStent™ for Catheter-dependent Urinary Retention Secondary to Benign Prostatic Hyperplasia: Additional Results From the RAPID I Study. Urology. 2025. PMID: 40967370. doi:10.1016/j.urology.2025.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。